TY - JOUR
T1 - Expression of Vascular Endothelial Growth Factor Receptors in Benign Vascular Lesions of the Orbit
T2 - A Case Series
AU - Atchison, Elizabeth A.
AU - Garrity, James A.
AU - Castillo, Francisco
AU - Engman, Steven J.
AU - Couch, Steven M.
AU - Salomaõ, Diva R.
N1 - Publisher Copyright:
© 2016 American Academy of Ophthalmology.
PY - 2016/1/1
Y1 - 2016/1/1
N2 - Vascular lesions of the orbit, although not malignant, can cause morbidity because of their location near critical structures in the orbit. For the same reason, they can be challenging to remove surgically. Anti-vascular endothelial growth factor (VEGF) drugs are increasingly being used to treat diseases with prominent angiogenesis. Our study aimed to determine to what extent VEGF receptors and their subtypes are expressed on selected vascular lesions of the orbit. Design Retrospective case series of all orbital vascular lesions removed by one of the authors (JAG) at the Mayo Clinic. Participants A total of 52 patients who underwent removal of vascular orbital lesions. Methods The pathology specimens from the patients were retrieved, their pathologic diagnosis was confirmed, demographic and clinical information were gathered, and sections from vascular tumors were stained with vascular endothelial growth factor receptor (VEGFR), vascular endothelial growth factor receptor type 1 (VEGFR1), vascular endothelial growth factor receptor type 2 (VEGFR2), and vascular endothelial growth factor receptor type 3 (VEGFR3). Main Outcome Measures The existence and pattern of staining with VEGF and its subtypes on these lesions. Results There were 28 specimens of venous malformations, 4 capillary hemangiomas, 7 lymphatic malformations, and 6 lymphaticovenous malformations. All samples stained with VEGF, 55% stained with VEGFR1, 98% stained with VEGFR2, and 96% stained with VEGFR3. Most (94%) of the VEGFR2 staining was diffuse. Conclusions Most orbital vascular lesions express VEGF receptors, which may suggest a future target for nonsurgical treatment.
AB - Vascular lesions of the orbit, although not malignant, can cause morbidity because of their location near critical structures in the orbit. For the same reason, they can be challenging to remove surgically. Anti-vascular endothelial growth factor (VEGF) drugs are increasingly being used to treat diseases with prominent angiogenesis. Our study aimed to determine to what extent VEGF receptors and their subtypes are expressed on selected vascular lesions of the orbit. Design Retrospective case series of all orbital vascular lesions removed by one of the authors (JAG) at the Mayo Clinic. Participants A total of 52 patients who underwent removal of vascular orbital lesions. Methods The pathology specimens from the patients were retrieved, their pathologic diagnosis was confirmed, demographic and clinical information were gathered, and sections from vascular tumors were stained with vascular endothelial growth factor receptor (VEGFR), vascular endothelial growth factor receptor type 1 (VEGFR1), vascular endothelial growth factor receptor type 2 (VEGFR2), and vascular endothelial growth factor receptor type 3 (VEGFR3). Main Outcome Measures The existence and pattern of staining with VEGF and its subtypes on these lesions. Results There were 28 specimens of venous malformations, 4 capillary hemangiomas, 7 lymphatic malformations, and 6 lymphaticovenous malformations. All samples stained with VEGF, 55% stained with VEGFR1, 98% stained with VEGFR2, and 96% stained with VEGFR3. Most (94%) of the VEGFR2 staining was diffuse. Conclusions Most orbital vascular lesions express VEGF receptors, which may suggest a future target for nonsurgical treatment.
UR - http://www.scopus.com/inward/record.url?scp=84951052286&partnerID=8YFLogxK
U2 - 10.1016/j.ophtha.2015.09.009
DO - 10.1016/j.ophtha.2015.09.009
M3 - Article
C2 - 26481818
AN - SCOPUS:84951052286
SN - 0161-6420
VL - 123
SP - 209
EP - 213
JO - Ophthalmology
JF - Ophthalmology
IS - 1
ER -